文献速递炎症性肠病消化道肿瘤与早癌

系统综述:炎症性肠病生物制剂治疗中的肝脾T细胞淋巴瘤

Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System.
PubMed 文献 · Aliment Pharmacol Ther · 2020-01-28

本研究通过文献检索和FDA不良事件报告系统查询,纳入62例有生物制剂暴露史的IBD相关HSTCL病例,中位年龄28岁,83.6%为男性,84.7%为克罗恩病。几乎所有病例均有硫唑嘌呤/巯嘌呤暴露,且所有生物制剂暴露病例均有抗TNF暴露;

要点

  • IBD患者使用生物制剂期间发生的HSTCL几乎均伴随硫唑嘌呤/巯嘌呤暴露。
  • 所有生物制剂暴露的HSTCL病例均有抗TNF暴露史。
  • 已知结局的HSTCL患者死亡率高(87.8%),中位生存仅5个月。

核心结论

  • IBD患者生物制剂治疗中发生的HSTCL几乎均伴有硫唑嘌呤/巯嘌呤暴露,且所有生物制剂暴露病例均有抗TNF暴露。
  • 这些数据提示在启动抗TNF或其他生物制剂前应与患者进行以患者为中心的讨论。

研究设计与样本

  • 系统综述,通过文献检索和FDA不良事件报告系统查询,纳入62例有生物制剂暴露史的IBD相关HSTCL病例。
  • 从2486篇摘要和181份FDA不良事件报告系统中识别病例,提取人口学和免疫抑制暴露信息。
  • 按当前方案(联合治疗、生物制剂单药或无生物制剂)和生物制剂类别(抗TNF、抗整合素、抗IL-12/23)进行分层。

主要发现

  • 62例HSTCL患者中位年龄28岁(范围12-81),83.6%为男性,84.7%为克罗恩病。
  • 62例中5例无硫唑嘌呤/巯嘌呤暴露报告;3例在暴露于那他珠单抗、维得利珠单抗或乌司奴单抗后发生HSTCL,但均有抗TNF和硫唑嘌呤/巯嘌呤暴露。

关键数值与推荐

  • HSTCL病例中位年龄28岁(范围12-81),男性占83.6%,克罗恩病占84.7%。

临床怎么用

  • 在启动抗TNF治疗或其他生物制剂前,应与IBD患者进行以患者为中心的讨论,告知HSTCL风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatosplenic T-cell lymphoma (HSTCL) is a rare, poorly treatable malignancy associated with therapy for IBD. Current knowledge of HSTCL risk in IBD comes from an era of step-up therapy, before earlier use of biologics or combination therapy was advocated to achieve deep mucosal healing. HSTCL risk among newer biologic classes has also not been evaluated. AIMS: To systematically characterise the association of HSTCL with biologic therapy for IBD. METHODS: We conducted a literature search and query of the Food and Drug Administration Adverse Event Reporting System to summarise HSTCL cases among IBD patients with prior biologic exposure. Demographics and immunosuppression exposure were extracted. Patients were stratified by current regimen (combination therapy, biologic monotherapy or no biologic), and biologic class (anti-TNF, anti-integrin, anti-interleukin 12/23). RESULTS: Sixty-two cases of HSTCL were identified from 2486 abstracts and 181 FDA Adverse Events Reporting System reports. The median age of affected patients was 28 years (range 12-81), and 83.6% were male, 84.7% had Crohn's disease. Five of 62 patients had no reported azathioprine/mercaptopurine exposure. Three patients within the cohort developed HSTCL after exposure to natalizumab, vedolizumab or ustekinumab; all three also had anti-TNF and azathioprine/mercaptopurine exposure. Forty-three of 49 (87.8%) patients with known outcomes died with a median survival of 5 months. CONCLUSIONS: Consistent with existing data, almost all identified HSTCL cases among IBD patients on biologic therapy had azathioprine/mercaptopurine exposure, and all cases on patients exposed to biologics had anti-TNF exposure. These data suggest initiating a patient-centred discussion before starting anti-TNF therapy or other biologics.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Shah ED, Coburn ES, Nayyar A, et al. Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System. Aliment Pharmacol Ther. 2020. PMID: 31990422. doi:10.1111/apt.15637

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。